Go to content
UR Home

Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?

URN to cite this document:
DOI to cite this document:
Hatzipanagiotou, Maria Eleni ; Pigerl, Miriam ; Gerken, Michael ; Räpple, Sophie ; Zeltner, Verena ; Hetterich, Madeleine ; Ugocsai, Peter ; Fernandez-Pacheco, Miriam ; Inwald, Elisabeth Christine ; Klinkhammer-Schalke, Monika ; Ortmann, Olaf ; Seitz, Stephan
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 12 Jul 2023 11:23

This publication is part of the DEAL contract with Springer.


Purpose For patients with triple negative breast cancer (TNBC), the optimal time to initiate neoadjuvant chemotherapy (TTNC) is unknown. This study evaluates the association between TTNC and survival in patients with early TNBC. Methods A retrospective study using data from of a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018 registered in the Tumor Centre ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons